sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
methylphenidate
|
cimetidine
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p6
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clonazepam
|
delavirdine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p334
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
metoclopramide
|
APOKYN
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p44
|
When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
|
indinavir
|
SUSTIVA
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s39
|
DDI-DrugBank.d531.s39.p0
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
monoamine oxidase inhibitors
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p6
|
Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
|
Diuretic
|
Hydrochlorothiazide
|
NONE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s10
|
DDI-DrugBank.d499.s10.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
cyclosporine
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p54
|
and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
|
cisapride
|
fluoxetine
|
NONE
|
11213850.xml
|
DDI-MedLine.d46.s9
|
DDI-MedLine.d46.s9.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
cimetidine
|
trazodone
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p94
|
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
|
gemifloxacin
|
magnesium
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s6
|
DDI-DrugBank.d347.s6.p2
|
CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
|
CELEBREX
|
fluconazole
|
ADVISE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s18
|
DDI-DrugBank.d172.s18.p0
|
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
|
ofloxacin
|
KRM-1648
|
EFFECT
|
11137650.xml
|
DDI-MedLine.d8.s6
|
DDI-MedLine.d8.s6.p0
|
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
|
heparin
|
vitamin K antagonists
|
NONE
|
Alteplase_ddi.xml
|
DDI-DrugBank.d508.s1
|
DDI-DrugBank.d508.s1.p0
|
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
|
Phospholine Iodide
|
organophosphate insecticide
|
EFFECT
|
Echothiophate Iodide_ddi.xml
|
DDI-DrugBank.d377.s0
|
DDI-DrugBank.d377.s0.p2
|
Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
|
amphotericin B
|
tubocurarine
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s12
|
DDI-DrugBank.d318.s12.p4
|
Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
|
cholestyramine
|
fluvastatin
|
EFFECT
|
19489169.xml
|
DDI-MedLine.d119.s16
|
DDI-MedLine.d119.s16.p0
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
ciprofloxacin
|
calcium
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p20
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
zinc
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p17
|
Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
|
propranolol
|
propranolol
|
NONE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s8
|
DDI-DrugBank.d565.s8.p4
|
Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
|
ascorbic acid
|
synthetic estrogens
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s14
|
DDI-DrugBank.d485.s14.p4
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
aminoglutethimide
|
ethionamide
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p13
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
|
methysergide
|
naratriptan
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s1
|
DDI-DrugBank.d478.s1.p9
|
Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
|
piperacillin
|
vecuronium
|
EFFECT
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s1
|
DDI-DrugBank.d462.s1.p2
|
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
|
Pulmozyme
|
vitamins
|
NONE
|
Dornase Alfa_ddi.xml
|
DDI-DrugBank.d93.s0
|
DDI-DrugBank.d93.s0.p2
|
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
|
Clonidine hydrochloride
|
alcohol
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s1
|
DDI-DrugBank.d495.s1.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
ziprasidone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p43
|
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
|
vitamins
|
corticosteroids
|
NONE
|
Dornase Alfa_ddi.xml
|
DDI-DrugBank.d93.s0
|
DDI-DrugBank.d93.s0.p12
|
Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
|
nifedipine
|
beta-blocking agents
|
EFFECT
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s0
|
DDI-DrugBank.d373.s0.p2
|
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
ketoconazole
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s7
|
DDI-DrugBank.d237.s7.p12
|
Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
|
phenytoin
|
valproic acid
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s15
|
DDI-DrugBank.d40.s15.p1
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
anesthetics
|
lidocaine
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p61
|
Some quinolones have also been shown to interfere with the metabolism of caffeine.
|
quinolones
|
caffeine
|
MECHANISM
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s13
|
DDI-DrugBank.d217.s13.p0
|
Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
|
flurbiprofen
|
beta-blocker
|
ADVISE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s11
|
DDI-DrugBank.d529.s11.p0
|
We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
|
ADL 8-2698
|
morphine
|
EFFECT
|
11180040.xml
|
DDI-MedLine.d87.s8
|
DDI-MedLine.d87.s8.p0
|
High-dose cisplatin with sodium thiosulfate protection.
|
cisplatin
|
sodium thiosulfate
|
EFFECT
|
4038510.xml
|
DDI-MedLine.d130.s0
|
DDI-MedLine.d130.s0.p0
|
Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
|
Piperacillin sodium
|
methotrexate
|
MECHANISM
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s7
|
DDI-DrugBank.d462.s7.p2
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
beta adrenergic blocking agents
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p7
|
Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
|
Rifabutin
|
rifampin
|
NONE
|
Atovaquone_ddi.xml
|
DDI-DrugBank.d424.s5
|
DDI-DrugBank.d424.s5.p1
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
sedatives
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p2
|
- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
|
isocarboxazid
|
Marplan
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s4
|
DDI-DrugBank.d521.s4.p13
|
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
|
ketoconazole
|
cisapride
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s7
|
DDI-DrugBank.d458.s7.p0
|
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
|
Furosemide
|
aminoglycoside antibiotics
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s0
|
DDI-DrugBank.d231.s0.p0
|
Trecator has been found to temporarily raise serum concentrations of isoniazid.
|
Trecator
|
isoniazid
|
MECHANISM
|
Ethionamide_ddi.xml
|
DDI-DrugBank.d166.s0
|
DDI-DrugBank.d166.s0.p0
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
narcotic analgesic
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p7
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
estrogens
|
levodopa
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p122
|
Aminoglutethimide diminishes the effect of coumarin and warfarin.
|
Aminoglutethimide
|
warfarin
|
EFFECT
|
Aminoglutethimide_ddi.xml
|
DDI-DrugBank.d372.s2
|
DDI-DrugBank.d372.s2.p1
|
There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
|
cetirizine
|
theophylline
|
MECHANISM
|
Cetirizine_ddi.xml
|
DDI-DrugBank.d393.s5
|
DDI-DrugBank.d393.s5.p0
|
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
|
resins
|
thiazide diuretics
|
NONE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s7
|
DDI-DrugBank.d46.s7.p25
|
The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
|
tricyclic antidepressants
|
cimetidine
|
EFFECT
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s4
|
DDI-DrugBank.d202.s4.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
alcohol
|
cholestyramine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p51
|
Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
|
erythromycin
|
terfenadine
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s9
|
DDI-DrugBank.d522.s9.p0
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
antimuscarinics
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p0
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
norepinephrine
|
monoamine oxidase inhibitors
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s0
|
DDI-DrugBank.d564.s0.p7
|
Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
|
cephalexin
|
metformin
|
MECHANISM
|
Cephalexin_ddi.xml
|
DDI-DrugBank.d303.s2
|
DDI-DrugBank.d303.s2.p0
|
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
|
Cholestyramine
|
resins
|
NONE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s7
|
DDI-DrugBank.d46.s7.p1
|
Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
|
Cytochalasin D
|
carbachol
|
EFFECT
|
11121387.xml
|
DDI-MedLine.d59.s4
|
DDI-MedLine.d59.s4.p0
|
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
|
verapamil
|
diltiazem
|
NONE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s17
|
DDI-DrugBank.d269.s17.p9
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
benzodiazepines
|
anticonvulsants
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p2
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
methsuximide
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p7
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
ACE inhibitors
|
salicylates
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s1
|
DDI-DrugBank.d527.s1.p5
|
Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
|
bupropion
|
hydroxybupropion
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s13
|
DDI-DrugBank.d5.s13.p1
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
fluoxetine
|
sertraline
|
NONE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s8
|
DDI-DrugBank.d223.s8.p18
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
enflurane
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p8
|
Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
|
fenoprofen
|
aspirin
|
MECHANISM
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s1
|
DDI-DrugBank.d154.s1.p0
|
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;
|
cocaine
|
nicotine
|
NONE
|
11085336.xml
|
DDI-MedLine.d110.s2
|
DDI-MedLine.d110.s2.p13
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
clarithromycin
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p4
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
CNS depressants
|
opiates
|
NONE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p8
|
Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
|
rifampicin
|
isradipine
|
MECHANISM
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s9
|
DDI-DrugBank.d81.s9.p3
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
tetracyclines
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p17
|
Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
|
cyclophosphamide
|
allopurinol
|
EFFECT
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s18
|
DDI-DrugBank.d413.s18.p4
|
Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
|
amiodarone
|
HMG-CoA reductase inhibitor class
|
EFFECT
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s12
|
DDI-DrugBank.d567.s12.p8
|
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
|
CANCIDAS
|
tacrolimus
|
NONE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s5
|
DDI-DrugBank.d350.s5.p1
|
Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
|
TRISENOX
|
antiarrhythmics
|
ADVISE
|
Arsenic trioxide_ddi.xml
|
DDI-DrugBank.d470.s1
|
DDI-DrugBank.d470.s1.p0
|
Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;
|
valproic acid
|
gabapentin
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s11
|
DDI-DrugBank.d438.s11.p2
|
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
|
diclofenac
|
warfarin
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s18
|
DDI-DrugBank.d249.s18.p3
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
aspirin
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p0
|
Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
|
guanethidine
|
ZEBETA
|
EFFECT
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s1
|
DDI-DrugBank.d476.s1.p2
|
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
|
hydrochlorothiazide
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s11
|
DDI-DrugBank.d345.s11.p13
|
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
|
Diuretic agents
|
lithium
|
EFFECT
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s10
|
DDI-DrugBank.d162.s10.p1
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
NSAIDs
|
ardeparin
|
EFFECT
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p13
|
Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
|
cyclosporine
|
norfloxacin
|
MECHANISM
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s3
|
DDI-DrugBank.d217.s3.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
chlordiazepoxide
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p21
|
In clinical studies, coadministration of WelChol with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
|
WelChol
|
simvastatin
|
NONE
|
Colesevelam_ddi.xml
|
DDI-DrugBank.d551.s4
|
DDI-DrugBank.d551.s4.p2
|
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
|
esomeprazole
|
ketoconazole
|
MECHANISM
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s12
|
DDI-DrugBank.d29.s12.p0
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
benzodiazepines
|
ethanol
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p4
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
CNS depressants
|
hypnotics
|
NONE
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p11
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
diazepam
|
risperidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p529
|
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
|
barbiturates
|
INAPSINE
|
EFFECT
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s0
|
DDI-DrugBank.d254.s0.p8
|
Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
|
alosetron
|
procainamide
|
EFFECT
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s15
|
DDI-DrugBank.d364.s15.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Topamax
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p10
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
nonsteroidal anti-inflammatory agents
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p0
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
Videx
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p43
|
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
|
(+)-NANM
|
(-)-NANM
|
NONE
|
3968644.xml
|
DDI-MedLine.d30.s6
|
DDI-MedLine.d30.s6.p3
|
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
|
Vardenafil
|
nitrates
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s24
|
DDI-DrugBank.d198.s24.p2
|
Amiodarone is known to raise serum digoxin levels.
|
Amiodarone
|
digoxin
|
MECHANISM
|
3964797.xml
|
DDI-MedLine.d61.s1
|
DDI-MedLine.d61.s1.p0
|
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
|
SSRI
|
sumatriptan
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s16
|
DDI-DrugBank.d568.s16.p5
|
Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
|
Antidepressants
|
tricyclic
|
NONE
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s3
|
DDI-DrugBank.d158.s3.p0
|
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
CNS depressants
|
antihistamines
|
NONE
|
Diphenylpyraline_ddi.xml
|
DDI-DrugBank.d168.s0
|
DDI-DrugBank.d168.s0.p7
|
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined.
|
pulmonary surfactant
|
Survanta
|
NONE
|
11064383.xml
|
DDI-MedLine.d18.s1
|
DDI-MedLine.d18.s1.p0
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
benzodiazepines
|
antidepressants
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p12
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.